January 02, 2019 Pharma news over the Christmas period If the recent performance of biotech stocks prompted you to pull down the shutters until the New Year celebrations subsided here’s what you might have missed.
September 11, 2018 No margin left for error at Acorda Generic versions of Acorda’s Ampyra are about to flood the market, meaning that the company desperately needs a timely approval in October for its next big hope.
September 01, 2017 Snippet roundup: The regulatory news is good for Lilly and Abbott, but bad for Acorda
April 03, 2017 Patent rulings knock Acorda and Forward Acorda and Forward have been bashed by unfavourable US patent verdicts in multiple sclerosis, while Steadymed got a boost.